GlassScriptPhysician profile
Ashton C Davis
NPI 1922872175
$1,603.69
in general payments reported to CMS, 2019-2025
23 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.41 · 2024: $891 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.61 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $210.68 | 2023-2025 | |
| Lilly USA, LLC | $179.24 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $140.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $98.83 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.65 | 2024-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $82.59 | 2023-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.73 | 2024-2025 | Xifaxan |
| Amgen INC. | $77.12 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $57.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.80 | 2024-2025 | |
| Radius Health, INC. | $48.52 | 2024-2025 | Tymlos |
| Dexcom, INC. | $36.54 | 2024 | Dexcom G6 Transmitter |
| Cequr Corporation | $29.90 | 2024-2025 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $25.26 | 2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $19.77 | 2024 | Venclose Maven Catheter |
| Axsome Therapeutics, INC. | $17.96 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $17.79 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $16.59 | 2024 | Vaxneuvance, Capvaxive, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.30 | 2025 | Caplyta |
| Tandem Diabetes Care, INC. | $16.22 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $14.39 | 2024 | Korlym |
| Averitas Pharma INC. | $13.13 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.